Form 4: Inmune Bio Director James Kelly Ganjei Acquires Options

Director James Kelly Ganjei acquired options to purchase 12,500 shares of Inmune Bio, Inc. common stock on May 14, 2024.

Summary

• On May 14, 2024, James Kelly Ganjei, a director of Inmune Bio, Inc., acquired options to purchase 12,500 shares of the company's common stock.
• The options were granted pursuant to the 2021 Stock Incentive Plan.
• The exercise price of the options is $9.92.
• The options vest in equal monthly installments over one year, becoming fully vested on May 14, 2025.
• The expiration date of the options is May 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an option grant to a director, which is neither particularly positive nor negative.

Positives

• The acquisition of options by a director may signal confidence in the company's future prospects.

Future Outlook

The options vest monthly over a year, suggesting a long-term incentive for the director.

Industry Context

This is a standard Form 4 filing, reflecting a transaction by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The option grant aligns the director's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates